gac,,,,no fear here,,,a tad of uncertainty and smiggin of doubt perhaps,,,back last April my conviction was that we would be in concurrent trials before BoM data would be returned to the public in December/18, as noted by DM and gang. $$$ were required to do so and our share price had tanked! ,,,no matter what financing was to occur it would mean dilution and based on their plan,,lots of it when related back to our share price at the time,,,, we now know concurrent trials was pie in the sky due to the inexperience of this RVX team around costs and trial timings. Do I think it is a mistake not having at the very least the CKD trial running concurrently these past few months??,,darn tooting I do..however..it certainly seems so viewing from the outside in that additional data makes much more sense when designing any of our orphan trials !!,,,but why wasnt that a pre-requisit back when Management made world wide presentations on timings,,it would certainly be a safety blanket if their timings were met here in what we may as well say is now mid Q1/19. jmo